Abstract:Background: T790M mutation detection in circulating tumor DNA (ctDNA) has shown great potential in clinical application. However, few studies reported the influence of plasma T790M mutation on selection of clinical treatment and survival time after first generation TKI resistance. Methods: 307 patients with advanced or recurrent NSCLC who had progressed during EGFR-TKIs treatment were enrolled prospectively (NCT02418234) from March 2015 to March 2016. Blood samples were drawn within two weeks from PD occurred. T790M mutations were evaluated by droplet digital PCR. We undertook follow-up every 3 months by phone till April 2017. The median follow-up time was 11 months (range, 2 to 22 months). Results: Our results showed that the median survival time after TKI progression was 17.5 months (95%CI, 15-20 months) and six kinds of treatments were used in these patients, including continuation of TKI (27.0%), AZD9291 (27.7%), chemotherapy with or without radiotherapy (15.3%), TKI combined with chemo/RT (6.5%), switch to another TKI (2.6%) and best supportive care (11.4%). 88.6% of patients received subsequent treatment. T790M- patients were likely to receive continuation of original TKIs, which accords for 29.5% (52/176), the percentage of switch to another TKI is the lowest (2.8%, 5/176). In T790M+ patients, AZD9291 is the first choice as the subsequent treatment, which accords for 38.9% (51/131). Switch to another TKI (2.2%, 3/131) and TKI combined with chemo/RT (6.1%, 8/131) is the least selection. Although most T790M- patients received continuation of original TKIs, combination of TKI and chemotherapy/radiotherapy seems to be a better choice, which got the longest survival than other treatment. For T790M+ patients, patients who choose AZD9291 had the longest survival. Conclusions: T790M status in ctDNA have the great influence on clinical decision of the subsequent treatment, AZD9291 is the most frequent choice for the plasma T790M+ patients, which contributed the longest survival after 1st generation EGFR-TKI resistance. Clinical trial identification: NCT02418234 Legal entity responsible for the study: Shenglin Ma Funding: Projects of Medical and Health Technology in Zhejiang Province (WKJ-2J-1532) Disclosure: All authors have declared no conflicts of interest.

Non-invasive and Quantitative Analysis for EGFR T790M Mutation in the Patients with Advanced Non-Small Cell Lung Cancer Received EGFR-TKI Therapy.

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC

Noninvasive Monitoring of Dynamics of Acquired Egfr-T790m Mutation and Discovery of Its Heterogeneity in Patients with Advanced Nsclc Treated with Egfr-Tki.

T790M Mutation is Associated with Better Efficacy of Treatment Beyond Progression with EGFR-TKI in Advanced NSCLC Patients.

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

P3.02b-098 Plasma T790M Mutation Associates with Extensive Progression in Non-small Cell Lung Cancer with Acquired Resistance to EGFR Inhibitors: Topic: EGFR RES

Comparison of Cross-Platform Technologies for EGFR T790M Testing in Patients with Non-Small Cell Lung Cancer

Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients

Quantitative Test of Mutant Egfr and Its Effect on Efficacy of Egfr Tki in Advanced Nsclc

Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients

Plasma Egfr T790m Ctdna Status is Associated with Clinical Outcome in Advanced Nsclc Patients with Acquired Egfr-Tki Resistance

A Sensitive and Practical Method to Detect the T790m Mutation in the Epidermal Growth Factor Receptor

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

Detecting T790M Mutation of Tissue and Plasma Ctdna Samples by ARMS in EGFR-mutant NSCLC Patients after Disease Progression.

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Influence of Plasma T790M Mutation on Clinical Decision after 1st Generation EGFR-TKI Resistance in a Real-world Study

Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs

Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients

Conventional Real-Time PCR-based Detection of T790M Using Tumor Tissue or Blood in Patients with EGFR TKI-resistant NSCLC

Establishment of a Digital PCR Platform for Detection of EGFR T790M Mutation in Plasma Circulating DNA from NSCLC Patients